{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:42:03Z","timestamp":1761964923526},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T00:00:00Z","timestamp":1507939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12185-017-2354-6","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T05:29:52Z","timestamp":1507958992000},"page":"495-497","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved"],"prefix":"10.1007","volume":"107","author":[{"given":"Yosuke","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Tachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikuni","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikatsu","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Saga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,14]]},"reference":[{"key":"2354_CR1","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","volume":"120","author":"J Cortes","year":"2012","unstructured":"Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390\u20137.","journal-title":"Blood"},{"key":"2354_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1532\/IJH97.06024","volume":"83","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol. 2006;83:289\u201393.","journal-title":"Int J Hematol"},{"key":"2354_CR3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cncr.11477","volume":"98","author":"H Kantarjian","year":"2003","unstructured":"Kantarjian H, O\u2019Brien S, Cortes J, Giles F, Thomas D, Kornblau S, et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003;98:81\u20135.","journal-title":"Cancer"},{"key":"2354_CR4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","volume":"107","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S, Rios MB, Abruzzo L, Verstovsek S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006;107:480\u20132.","journal-title":"Blood"},{"key":"2354_CR5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3109\/10428194.2011.652108","volume":"53","author":"A Tantiworawit","year":"2012","unstructured":"Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, et al. Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leuk Lymphoma. 2012;53:1321\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2354_CR6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cncr.22046","volume":"107","author":"G Alimena","year":"2006","unstructured":"Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, Biondo F, et al. Sudden blast crisis in patients with philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer. 2006;107:1008\u201313.","journal-title":"Cancer"},{"key":"2354_CR7","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1038\/bcj.2016.66","volume":"6","author":"MK Angelopoulou","year":"2016","unstructured":"Angelopoulou MK, Asimakopoulos JV, Galani Z, Levidou G, Roumelioti M, Vassilakopoulos TP, et al. Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib. Blood Cancer J. 2016;6:e461.","journal-title":"Blood Cancer J"},{"key":"2354_CR8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","volume":"16","author":"AS Shet","year":"2002","unstructured":"Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia. 2002;16:1402\u201311.","journal-title":"Leukemia"},{"key":"2354_CR9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2354_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.critrevonc.2010.07.003","volume":"79","author":"M Breccia","year":"2011","unstructured":"Breccia M, Alimena G. The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. Crit Rev Oncol Hematol. 2011;79:135\u201343.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2354_CR11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415\u201324.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2354-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T13:26:09Z","timestamp":1521033969000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2354-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,14]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2354-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,14]]}}}